| 摘要 |
This invention has for its object to insure an effective utilization of single-stranded nucleic acid copolymers, particularly poly(adenylic acid-uridylic acid), and to provide a pharmaceutical composition having antitumor activity. The invention typically relates to a pharmaceutical composition comprising a lipid device such as Lipofectin (trademark), 3-0-(4-dimethylaminobutanoyl)-1,2-0-dioleylgycerol, 3-0-(2-dimethylamino-ethyl)carbamoyl-1,2-0-dioleylglycerol, 3-0-(2-diethylaminoethyl) carbamoyl-1,2-0-dioleylgycerol, or 2-0-(2-diethylaminoethyl)carbamoyl-1,3-0-dioleoylglycerol and poly(adenylic acid-uridylic acid).
|
